We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SEC61A1 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
168.2
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
356.3
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
333.7
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
297.6
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
295.0
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
286.6
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
285.4
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
274.6
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
269.9
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
267.9
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
263.1
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
257.1
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
252.0
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
246.8
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
243.2
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
237.3
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
233.3
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
225.4
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
225.1
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
221.9
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
221.5
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
220.8
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
219.7
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
219.6
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
218.8
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
217.5
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
217.1
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
215.7
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
215.6
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
215.5
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
213.5
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
212.1
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
209.3
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
207.0
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
205.5
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
205.5
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
204.5
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
204.3
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
204.2
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
202.9
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
202.3
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
201.8
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
201.2
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
200.5
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
198.9
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
198.3
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
194.8
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
194.5
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
192.9
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
191.6
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
191.1
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
190.8
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
190.8
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
189.1
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
186.2
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
185.3
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
184.5
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
184.1
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
182.0
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
181.9
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
181.3
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
180.7
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
180.7
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
175.4
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
175.0
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
172.9
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
172.4
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
171.5
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
169.5
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
167.6
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
167.6
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
165.6
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
165.3
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
163.9
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
163.8
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
163.1
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
162.5
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
162.0
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
160.6
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
160.4
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
160.3
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
159.8
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
158.7
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
158.6
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
158.0
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
156.9
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
156.8
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
156.8
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
154.6
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
152.9
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
151.9
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
148.4
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
146.3
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
146.2
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
146.1
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
145.5
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
145.1
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
143.2
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
142.8
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
142.4
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
139.7
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
139.2
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
135.1
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
130.6
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
129.3
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
128.3
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
126.8
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
125.1
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
123.1
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
122.6
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
122.0
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
121.9
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
120.8
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
120.6
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
117.6
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
108.8
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
106.7
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
103.9
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
103.7
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
103.5
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
102.8
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
102.5
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
99.8
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
99.0
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
95.8
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
95.4
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
94.8
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
92.5
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
89.9
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
88.9
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
87.5
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
85.0
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
82.0
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
78.0
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
78.0
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
72.2
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
55.9
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
54.1
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
51.0
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SEC61A1 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
64.5
Number of samples
58
Samples
Sample
Description
TPM
AK153
N, NA, stage:NA, dead, 240 days
162.9
AK003
N, NA, stage:NA, dead, 600 days
105.4
AK051
N, NA, stage:NA, dead, 360 days
103.4
AK076
N, NA, stage:NA, alive, 660 days
101.2
AK236
N, NA, stage:NA, dead, 360 days
95.6
AK227
N, NA, stage:NA, alive, 300 days
87.4
AK183
N, NA, stage:NA, alive, 360 days
85.2
AK188
N, NA, stage:NA, alive, 420 days
84.8
AK199
N, NA, stage:NA, alive, 1860 days
81.3
AK216
N, NA, stage:NA, dead, 360 days
79.1
AK149
N, NA, stage:NA, dead, 420 days
77.6
AK055
N, NA, stage:NA, dead, 240 days
77.3
AK139
N, NA, stage:NA, dead, 270 days
75.6
AK098
N, NA, stage:NA, dead, 660 days
75.2
AK071
N, NA, stage:NA, dead, 540 days
74.2
AK100
N, NA, stage:NA, alive, 960 days
72.4
AK053
N, NA, stage:NA, dead, 300 days
72.0
AK218
N, NA, stage:NA, dead, 180 days
71.9
AK178
N, NA, stage:NA, dead, 240 days
71.7
AK072
N, NA, stage:NA, dead, 150 days
68.6
AK213
N, NA, stage:NA, alive, 2010 days
67.4
AK123
N, NA, stage:NA, dead, 180 days
66.3
AK043
N, NA, stage:NA, alive, 660 days
65.7
AK035
N, NA, stage:NA, dead, 210 days
64.6
AK185
N, NA, stage:NA, alive, 330 days
63.8
AK068
N, NA, stage:NA, alive, 360 days
63.3
AK142
N, NA, stage:NA, alive, 90 days
62.8
AK091
N, NA, stage:NA, dead, 210 days
62.7
AK005
N, NA, stage:NA, dead, 240 days
62.5
AK133
N, NA, stage:NA, dead, 360 days
62.5
AK088
N, NA, stage:NA, dead, 360 days
62.4
AK002
N, NA, stage:NA, dead, 570 days
61.8
AK089
N, NA, stage:NA, dead, 330 days
61.2
AK195
N, NA, stage:NA, dead, 390 days
59.8
AK117
N, NA, stage:NA, dead, 210 days
58.5
AK165
N, NA, stage:NA, alive, 360 days
58.0
AK226
N, NA, stage:NA, dead, 360 days
57.9
AK074
N, NA, stage:NA, alive, 300 days
56.9
AK099
N, NA, stage:NA, dead, 420 days
56.6
AK049
N, NA, stage:NA, dead, 180 days
56.2
AK079
N, NA, stage:NA, dead, 210 days
54.1
AK156
N, NA, stage:NA, dead, 330 days
52.2
AK085
N, NA, stage:NA, alive, 660 days
52.1
AK173
N, NA, stage:NA, dead, 180 days
51.7
AK081
N, NA, stage:NA, dead, 180 days
50.7
AK103
N, NA, stage:NA, alive, 1320 days
50.1
AK030
N, NA, stage:NA, dead, 120 days
48.6
AK041
N, NA, stage:NA, alive, 810 days
48.4
AK205
N, NA, stage:NA, dead, 120 days
44.4
AK134
N, NA, stage:NA, dead, 360 days
43.9
AK231
N, NA, stage:NA, dead, 240 days
43.7
AK158
N, NA, stage:NA, dead, 360 days
43.6
AK066
N, NA, stage:NA, alive, 960 days
42.9
AK124
N, NA, stage:NA, alive, 1920 days
41.5
AK006
N, NA, stage:NA, dead, 360 days
37.5
AK167
N, NA, stage:NA, dead, 180 days
35.5
AK102
N, NA, stage:NA, alive, 1740 days
28.4
AK015
N, NA, stage:NA, alive, 720 days
23.0
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0206560003
Tumor
1.7
CPT0217430008
Tumor
0.9
CPT0078580003
Tumor
0.8
CPT0207090003
Tumor
0.7
CPT0093450003
Tumor
0.7
CPT0167970003
Tumor
0.6
CPT0218330004
Tumor
0.6
CPT0093510003
Tumor
0.6
CPT0168080003
Tumor
0.5
CPT0205780003
Tumor
0.5
CPT0205450004
Tumor
0.5
CPT0127480003
Tumor
0.5
CPT0167640003
Tumor
0.5
CPT0093360003
Tumor
0.5
CPT0224390004
Tumor
0.4
CPT0087680003
Tumor
0.4
CPT0206000004
Tumor
0.4
CPT0168480003
Tumor
0.4
CPT0206230003
Tumor
0.4
CPT0190360004
Tumor
0.4
CPT0206670004
Tumor
0.4
CPT0162100003
Tumor
0.4
CPT0206780003
Tumor
0.3
CPT0218830004
Tumor
0.3
CPT0093550003
Tumor
0.3
CPT0209440003
Tumor
0.3
CPT0217060003
Tumor
0.3
CPT0079790003
Tumor
0.3
CPT0093590003
Tumor
0.3
CPT0123530003
Tumor
0.3
CPT0162140003
Tumor
0.3
CPT0218690004
Tumor
0.2
CPT0087950003
Tumor
0.2
CPT0218890004
Tumor
0.2
CPT0182580003
Tumor
0.2
CPT0217710008
Tumor
0.2
CPT0168590003
Tumor
0.2
CPT0167750004
Tumor
0.2
CPT0167530003
Tumor
0.2
CPT0186100003
Tumor
0.2
CPT0168830003
Tumor
0.2
CPT0089150003
Tumor
0.2
CPT0189750004
Tumor
0.1
CPT0182500003
Tumor
0.1
CPT0224540004
Tumor
0.1
CPT0168720003
Tumor
0.1
CPT0125510003
Tumor
0.1
CPT0219080004
Tumor
0.1
CPT0225760003
Tumor
0.0
CPT0217100003
Tumor
0.0
CPT0206880003
Tumor
0.0
CPT0206450003
Tumor
0.0
CPT0208980003
Tumor
0.0
CPT0125570003
Tumor
0.0
CPT0205570003
Tumor
0.0
CPT0217880003
Tumor
0.0
CPT0161730003
Tumor
0.0
CPT0104330003
Tumor
0.0
CPT0087570003
Tumor
0.0
CPT0217190003
Tumor
0.0
CPT0168270003
Tumor
0.0
CPT0071100003
Tumor
0.0
CPT0189850004
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0162020003
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0087730003
Tumor
-0.1
CPT0002410011
Tumor
-0.1
CPT0224600003
Tumor
-0.1
CPT0217000004
Tumor
-0.1
CPT0189570004
Tumor
-0.1
CPT0205670004
Tumor
-0.1
CPT0218770003
Tumor
-0.1
CPT0218960004
Tumor
-0.1
CPT0221180003
Tumor
-0.1
CPT0225730003
Tumor
-0.1
CPT0196850003
Tumor
-0.1
CPT0206110003
Tumor
-0.2
CPT0216920008
Tumor
-0.2
CPT0127420003
Tumor
-0.2
CPT0189250003
Tumor
-0.2
CPT0167860004
Tumor
-0.2
CPT0171580008
Tumor
-0.2
CPT0175060003
Tumor
-0.2
CPT0064650003
Tumor
-0.3
CPT0189460003
Tumor
-0.3
CPT0168380003
Tumor
-0.3
CPT0092440003
Tumor
-0.3
CPT0207030003
Tumor
-0.3
CPT0189650004
Tumor
-0.3
CPT0201710003
Tumor
-0.3
CPT0205890003
Tumor
-0.3
CPT0224330003
Tumor
-0.4
CPT0199770003
Tumor
-0.4
CPT0218670003
Tumor
-0.4
CPT0228220003
Tumor
-0.5
CPT0182550003
Tumor
-0.5
CPT0104220003
Tumor
-0.5
CPT0206330003
Tumor
-0.5
CPT0190240004
Tumor
-0.6
CPT0204360003
Normal
-0.7
CPT0204380003
Normal
-0.7
CPT0204410003
Normal
-0.9
CPT0204330003
Normal
-0.9
CPT0204350003
Normal
-0.9
CPT0204340003
Normal
-1.0
CPT0204390003
Normal
-1.0
CPT0204400003
Normal
-1.1
CPT0204370003
Normal
-1.2
CPT0204420003
Normal
-1.2
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.